ResMed announces strategy, outlook 

SAN DIEGO – ResMed unveiled its 2030 strategy to drive growth, profitability and shareholder returns, including investing 7% in R&D, at an Investor Day in New York City. 

The company also announced its five-year revenue and earnings growth outlook, reflecting its plans to accelerate product and technology innovation, operational excellence, commercial execution and financial strength. 

“By building on our leadership in connected digital health, our 2030 Strategy will further enable us to transform sleep health, breathing health, and health tech at home through world-class products and digital solutions,” said Mick Farrell, chairman and CEO. “We remain focused on delivering a more integrated and intelligent ResMed ecosystem, transforming the consumer and provider experience to offer better care, simplify the health journey, and improve access to our therapies. As we grow our core sleep apnea market, we will also leverage our strong financial position and expertise in broader sleep health to expand into adjacent markets and accelerate the release of new products at an unprecedented velocity.” 

ResMed’s 2030 strategy will focus on three pillars to drive growth: 

• Grow and differentiate its core sleep apnea franchise, led by demand generation and demand capture; 
• Capitalize on its market opportunity and brand advantage in broader sleep health and breathing health adjacencies; and 
• Invest 7% of revenue into R&D to invent, create and differentiate a fully integrated ecosystem for health technology delivered at home. 

ResMed’s five-year financial outlook includes high single-digit revenue growth and earnings growth higher than revenue growth. 

“Since our last Investor Day in 2021, we have delivered on our commitments, and this new outlook reinforces that ResMed is well positioned to maintain its track record of strong financial performance,” said Brett Sandercock, CFO. “Our financial strength and low capital requirements create robust cash generation, and our capital allocation strategy will continue to prioritize innovation – through reinvestment in our core business, a disciplined and strategic approach to M&A, and a balanced capital return policy. We are confident this approach will deliver significant value to shareholders as we execute our 2030 Strategy.”